INC Research has acquired NDDO Oncology, BV, a global Contract Research Organization (CRO) known as a leader in the field of anticancer drug development.
“With the addition of NDDO Oncology, INC Research becomes a predominant global leader in our therapeutically specialized service sector,” stated Jim Ogle, CEO of INC Research. “Our Pharma and Biotech customers are focused on finding outsourcing partners with both specialized expertise and access to experienced investigators. NDDO’s renowned oncology capabilities and strong ties to oncology investigators and thought leaders worldwide bring considerable strategic value to our organization and will have an immediate impact on the level of specialized expertise and service we can offer our customers. It’s a pleasure to welcome NDDO Oncology into the INC Research fold, and Coen van Kalken, MD, their founding CEO onto the INC Research Board of Directors.”
Kelvin Logan, PhD, President of INC Research Europe, said, “The managing executives of NDDO Oncology and their entire team will be a real asset to INC Research. I am confident they will quickly become an integral part of INC Research, augmenting the depth of scientific, clinical and regulatory expertise represented within our company. We are pleased to add this strong base of clinical operations in the Netherlands and additional expertise in early phase Oncology clinical studies in Europe.”
